DNA methylation patterns may explain why some prostate cancers turn lethal
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million American men, with another 330,000 men expected to be diagnosed with the condition this year alone.
Most prostate cancers arise late in life. The tumors grow slowly and remain in the prostate. However, there are several hundred thousand cases in which the cancer is more aggressive and grows quickly, spreading beyond the prostate into lymph nodes and bone.
Understanding why some prostate cancers grow slowly while others metastasize and become lethal is the central clinical question of prostate cancer management. If researchers could decipher the underlying pathology and predict a tumor's course of behavior, clinicians could avoid overtreating many patients while focusing on improving treatment for those with the most aggressive cases.
Paul C. Boutros, Ph.D., MBA, is a professor and director of the National Cancer Institute-designated cancer center at Sanford Burnham Prebys Medical Discovery Institute. In previous research, he and colleagues discovered that permanent changes in prostate cancer DNA, called somatic mutations, shape the aggressiveness of cancers.
But this discovery led to a major new question: How do changes in the DNA lead to changes in the cancers that affect growth rates and response to therapy?
In a new paper, published in the journal Cancer Discovery, senior author Boutros and an international team of co-authors identify the answer: prostate tumor methylation.
Methylation is a fundamental process in cell biology that involves chemical tags called methyl groups being attached to specific DNA segments. The process turns certain genes on or off.
In cancer, methylation can reveal how a tumor is likely to behave or respond to treatments. Because methylation changes happen to DNA after mutations occur, it serves as the key link between cancer genetics and patient outcomes.
To fully define this process, Boutros and colleagues created a compendium of 3,001 multi-ancestry prostate methylomes (a complete set of DNA methylation modifications) spanning normal tissue through localized prostate disease of all grades to advanced metastatic disease. A subset of 884 samples also had multi-omic DNA and/or RNA characterization. Samples for this study came from around the world.
Boutros' team found that of the millions of potential methylation patterns in prostate cancer, four specific patterns were extremely common. These so-called "methylation subtypes" recurred across patients and closely reflected the clinical aggressiveness of cancers.
One subtype was associated with normal aging prostate and extremely slow-growing cancers. Two subtypes were associated with prostate cancers that tended to grow at a moderate pace, but rarely moved out of the prostate. And the final subtype almost exclusively occurred in prostate cancers that metastasized and became lethal.
Not only did methylation patterns replicate in thousands of patients, Boutros said, but they also exhibited highly predictable patterns across age, ancestry and even the specific DNA mutations that occurred in each patient's cancer.
"Methylation was the way the cancer took the information from cancer genetics, patient lifestyle and other features and created a single signal that we could read," said Boutros. "That made it an ideal biomarker, and helped us learn what really makes prostate cancers so common, and so dangerous."
Takafumi Yamaguchi, a bioinformatician at Sanford Burnham Prebys and co-lead author of the study, noted the multidisciplinary collaboration underlying the research.
"A study like this is a beautiful, complex dance. There were 22 separate institutions from around the world working together. We needed to find ways for cancer biologists and statisticians to talk with urologists, radiation oncologists and pathologists. Many of the technologies, and the AI and data science techniques we used, didn't exist just 10 years ago, so there was a lot of learning for everyone!"
"Every research study leads to new questions," said Boutros, discussing next steps. "First and most importantly, we now want to work out how to get this information into prostate cancer clinics to help patients and their caregivers get the best possible treatment.
"Secondly, several parts of this study hint that oxygen flow in the prostate may be very important. We are going to test whether light exercise and similar strategies can help reduce the incidence of aggressive prostate cancer in clinical trials."
Publication details
Jaron Arbet et al, The Landscape of Prostate Tumour Methylation, Cancer Discovery (2026). DOI: 10.1158/2159-8290.cd-25-0761
Journal information: Cancer Discovery
Key medical concepts
Clinical categories
OncologyUrologyMen's healthCommon illnesses & Prevention Provided by Sanford-Burnham Prebys Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: DNA methylation patterns may explain why some prostate cancers turn lethal (2026, July 1) retrieved 1 July 2026 from https://medicalxpress.com/news/2026-07-dna-methylation-patterns-prostate-cancers.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.